Solid Tumor Clinical Trials
AB598
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants with Advanced Malignancies
PRECISION 1
A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
CRB-701
A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701, an Antibody-drug Conjugate Targeting Nectin-4, in Patients with Advanced Solid Tumors.
GCT 1042
Malignant Solid Tumors (NSCLS-PD-L1+TPS>1%, HNSCC-PDL-1+CPS>20%).
TSC-007
Phase 2 - Nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes.
ARC-25
Phase 1/1b - Advanced Malignancies - Metastatic, solid tumors having proven standard therapy as ineffective or intolerable.).
CRB-701
Phase 1/2 - An anti-body drug conjugate targeting Nectin-4 in patients with advanced Solid Tumors. Having Progressed on 1L Therapy.
ART_0380
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors.